AlzeCure will receive an upfront payment of USD 10 million USD, development and commercial milestones, and tiered mid-single digit royalties on sales. The total deal value, excluding royalty payments, may exceed USD 1 billion USD.

Alzstatin ACD680

Alzstatin ACD680 is a gamma-secretase modulator that aims to reduce the production of the harmful amyloid-beta protein, Aβ42, which forms the building blocks of the amyloid plaques found in the brains of Alzheimer’s patients. In addition, ACD680 is designed to increase the production of shorter, benign Aβ proteins, Aβ37 and Aβ38, which may reduce the aggregation of Aβ42, thereby also reducing the build-up of harmful plaques in the brain.
 
“Gamma-secretase modulators, which we have developed within the Alzstatin platform, are small-molecule drugs where the mechanism has a strong genetic link to the disease,” says Johan Sandin, Chief Scientific Officer at AlzeCure Pharma.
 
“The Alzstatin compounds are hoped to be used to counteract re-accumulation of harmful amyloid in the brain. In the long term, these compounds may also serve as a preventive treatment to prevent the development of Alzheimer’s disease,” says AlzeCure’s CEO Martin Jönsson.